Clinical Trial Update: BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating faldaprevir (BI 207127) in combination therapy for genotype 1b chronic hepatitis C in patients with hepatic impairment (Child-Pugh B); …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Faldaprevir (faldaprevir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20